Announcement PDF RNS Number : 0200M ValiRx PLC 09 June 2025 9 June 2025 ValiRx ("VAL" or the "Company") ValiRx Investor Webinar London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, is pleased to announce a post-Results webinar with CEO Mark Eccleston. The webinar will be hosted live via our website on Thursday, 12 June 2025 at 10am BST, and we invite both existing and prospective investors to submit their questions in advance. You can do so from here: https://valirx.com/webinars/XyO1Xr-annual-results-fy2024 For further information, please contact: Investor questions on this announcement We encourage all investors to share questions on this announcement via our investor hub https://valirx.com/link/lyapKP ValiRx plc Dr Mark Eccleston, CEO Tel:+44 115 784 0025 www.valirx.com Mark.Eccleston@valirx.com Cairn Financial Advisers LLP (Nominated Adviser) Tel: +44 (0) 20 7213 0880 Liam Murray / Ludovico Lazzaretti Shard Capital Partners LLP (Sole Broker) Tel: +44 (0) 20 7186 9000 Damon Heath V Formation (Public Relations) Lucy Wharton - Senior PR Executive Sue Carr - Director +44 (0) 115 787 0206 www.vformation.biz lucy@vformation.biz sue@vformation.biz Subscribe to our news alert service:https://valirx.com/s/f298d1 Notes for Editors About ValiRx ValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives. ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development. Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets. ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance. Lead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation. ValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL. For further information, visit:www.valirx.com This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END MSCSSLSUUEISEIM